Alector Inc (NASDAQ:ALEC) Insider Sells $46,161.00 in Stock
Alector Inc (NASDAQ:ALEC) insider Sabah Oney sold 2,300 shares of the company’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $20.07, for a total transaction of $46,161.00. Following the completion of the sale, the insider now directly owns 595,418 shares in the company, valued at $11,950,039.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Sabah Oney also recently made the following trade(s):
- On Friday, December 6th, Sabah Oney sold 5,156 shares of Alector stock. The shares were sold at an average price of $20.02, for a total transaction of $103,223.12.
ALEC stock opened at $19.93 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 6.57 and a quick ratio of 6.56. Alector Inc has a 1-year low of $13.64 and a 1-year high of $27.00. The firm has a fifty day moving average price of $17.33 and a two-hundred day moving average price of $17.54. The firm has a market cap of $1.32 billion and a price-to-earnings ratio of -4.31.
Hedge funds have recently added to or reduced their stakes in the business. Metropolitan Life Insurance Co NY bought a new stake in Alector during the third quarter valued at $150,000. California Public Employees Retirement System bought a new stake in Alector during the third quarter valued at $157,000. Voya Investment Management LLC bought a new stake in Alector during the third quarter valued at $165,000. Virtus ETF Advisers LLC bought a new stake in Alector during the second quarter valued at $251,000. Finally, Wells Fargo & Company MN increased its stake in Alector by 89.2% during the second quarter. Wells Fargo & Company MN now owns 13,650 shares of the company’s stock valued at $259,000 after purchasing an additional 6,434 shares during the last quarter. Hedge funds and other institutional investors own 50.02% of the company’s stock.
Several research firms recently issued reports on ALEC. Zacks Investment Research raised shares of Alector from a “sell” rating to a “hold” rating in a report on Monday, November 11th. Cowen reaffirmed a “buy” rating on shares of Alector in a report on Sunday, December 8th. ValuEngine cut shares of Alector from a “buy” rating to a “hold” rating in a report on Friday, September 27th. Finally, BTIG Research started coverage on shares of Alector in a report on Wednesday, November 27th. They issued a “buy” rating and a $28.00 price target on the stock. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Alector presently has an average rating of “Buy” and an average target price of $27.00.
Alector, Inc, a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease.
Recommended Story: What is meant by holder of record?
Receive News & Ratings for Alector Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alector and related companies with MarketBeat.com's FREE daily email newsletter.